Watson, Biovail settle patent dispute
Drug developer Watson Pharmaceuticals Inc. said Tuesday it will launch a version of Biovail Corp.'s blood pressure drug Cardizem L.A. after the companies settled a patent dispute. (AP, 8:22 a.m.)

Ahead of the Bell: Cephalon upgraded
A Friedman Billings Ramsey analyst upgraded shares of biotechnology company Cephalon Inc. Tuesday, saying sales of cancer drug candidate Treanda will be better than investors think. (AP, 7:49 a.m.)

Bruker makes $914m acquisition
NEW YORK - Bruker BioSciences Corp. , the maker of X-ray and research equipment, will buy closely held Bruker BioSpin for $914 million in cash and stock. The disclosure drove the price of the acquiring company to the highest in more than seven months on the Nasdaq Stock Market. (Boston Globe, 12 a.m.)

Patrick invokes historic link to China
BEIJING - On his first foreign trade mission, Governor Deval L. Patrick yesterday told a Beijing audience Massachusetts and China have had a "special trade relationship" that spans more than two centuries. Patrick noted the first US merchant ship to sail for China - in 1784 - had Boston owners. (Boston Globe, 12 a.m.)

Movers roundup: Intersil, Genentech
Analog chip maker Intersil Corp. rose Monday after a Pacific Crest Securities analyst said he believed the company had captured a 20 percent share in Advanced Micro Devices' upcoming PUMA notebook computer chipset. (AP, 12/3/07)

BioMarin partners on kidney disease drug
Biotechnology company BioMarin Pharmaceutical Inc. said Monday it is collaborating with privately held IGAN Biosciences to develop an enzyme therapy for a rare form of kidney disease. (AP, 12/3/07)

Sector Glance: Biotech stocks fall
Shares of most biotechnology companies followed the overall market lower Monday, while several stocks moved on drug development outlooks. (AP, 12/3/07)

Genentech shares fall on Avastin issues
Shares of biotechnology company Genentech Inc. fell Monday after the Food and Drug Administration said it would ask outside experts for a recommendation on whether Avastin should be approved to treat breast cancer. (AP, 12/3/07)

Isis executive VP exercises options
An executive vice president of drug developer Isis Pharmaceuticals Inc. exercised options for 20,000 shares of common stock under a prearranged trading plan, according to a Securities and Exchange Commission filing Friday. (AP, 12/3/07)

Questcor ships 1,060 vials of Acthar
Questcor Pharmaceuticals Inc. shipped 1,060 vials of multiple sclerosis drug H.P. Acthar Gel in October and November for distribution to hospitals and specialty pharmacies in the U.S, the company disclosed Monday. (AP, 12/3/07)